ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Dermavant raises $200m to support tapinarof launch pharmaceutical-technology
June 10, 2021Dermavant Sciences has signed a $160m revenue interest purchase and sale agreement for tapinarof with Marathon Asset Management, NovaQuest Capital Management and a third unnamed institutional investor in the US. -
Dermavant sells Tapinarof commercial rights in Japan pharmaceutical-technology
January 19, 2020Dermavant Sciences, a subsidiary of Roivant Sciences, has signed an exclusive agreement to sell the development and commercial rights of tapinarof in Japan.
Pharma Sources Insight January 2025
